Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revusiran in Post-Transplant FAP
NCT02595983Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Oct 2015
- Primary completion
- Feb 2017
- Modality
- Gene Editing, Gene Silencing, Conjugated siRNA
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of revusiran in familial amyloid polyneuropathy (FAP), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Percentage Change From Baseline in Serum TTR at Month 6. Started Oct 2015; status: completed.
02
Drugs
revusiran
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on NCT02595983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595983.